1518. Prevalence of Integrase Inhibitor Resistance within an Urban Clinic Network After Adoption as First-line Therapy

BACKGROUND: Limited data outside of randomized controlled trials exist reporting the prevalence of integrase inhibitor resistance (INSTI-R) since the approval and recommendation of INSTIs as first-line treatment for HIV. National surveillance data in 2018 estimated INSTI-R to be 6.3% in people with...

Descripción completa

Detalles Bibliográficos
Autores principales: Januszka, Jenna E, Drweiga, Emily N, Badowski, Melissa E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677931/
http://dx.doi.org/10.1093/ofid/ofad500.1353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677931/
http://dx.doi.org/10.1093/ofid/ofad500.1353

Ejemplares similares